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A recent genome-wide association (GWA) study confirmed 
108 genetic loci that were strongly associated with schiz-
ophrenia. Fifteen schizophrenia-associated genes were 
selected for this study based on a number of selection cri-
teria including their high expression in both brain tissues 
and B-lymphocyte cells. We aimed to investigate whether 
individuals with schizophrenia showed different levels of 
plasma IgG antibodies against protein-derived fragments 
encoded by these 15 genes. A total of 356 plasma samples 
were used to analyze circulating IgG antibodies against 18 
target peptide antigens using an in-house enzyme-linked 
immunosorbent assay. Of 18 antigens tested, 6 (derived 
from DPYD, MAD1L1, ZNF804A, DRD2, TRANK1, 
and MMP16, respectively) showed increased IgG lev-
els and 3 (derived from TSNARE1, TCF4, and VRK2, 
respectively) showed decreased IgG levels in patients with 
schizophrenia compared with control subjects. Receiver 
operating characteristic (ROC) curve analysis revealed 
that the anti-TRANK1 IgG assay had the area under 
the ROC curve of 0.68 (95% CI = 0.62–0.73), with the 
highest sensitivity of 20.7% against specificity of 95.2% 
among all 18 tests. There was no difference in positivity 
of anti-double strand DNA IgG between the patient group 
and the control group and no correlation between total 
IgG levels and each individual IgG level tested. Although 
risperidone treatment showed confounding effects on over-
all IgG levels in the circulation (combined P = .005), anti-
TRANK1 IgG levels did not appear to be significantly 
affected (t = 1.358, P =  .176). In conclusion, this study 
suggests that circulating anti-TRANK1 IgG is likely to 
serve as a biomarker for identification of a subgroup of 
schizophrenia.
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Introduction
The World Health Organization identifies schizophrenia 
as one of the top 10 causes of disability for both men and 
women, affecting around 0.7% of the population world-
wide.1 Antipsychotic medication is the first line treatment 
of schizophrenia but 20%–30% of patients do not have 
a good response to antipsychotic treatment. Although 
clozapine can be effective in up to one-third of patients, 
side effects are severe.2 A definitive etiology for the devel-
opment of schizophrenia remains complex and unclear, 
suggesting that there may be a number of underlying 
mechanisms involved. The most well-documented bio-
chemical mechanisms are the disturbances of dopamine 
and glutamate systems, although dysfunction of these 
neurotransmitter systems cannot account for all cases 
and psychotic symptoms.3
Schizophrenia is a highly heritable disease with complex 
modes of transmission. A  recent genome-wide associa-
tion (GWA) study analyzed more than 30 000 case–con-
trol samples and confirmed 108 genetic loci significantly 
associated with risk of the disease.4 The expression levels 
of the candidate genes in most loci were found to be the 
highest in brain tissues and B-lymphocytes (CD20+ and 
CD19+ cells) over 50 human tissues and cell lines ana-
lyzed, supporting the hypothesis that an immunological 
component is likely to be involved in the development of 
schizophrenia.4 Further support of an autoimmune role 
in schizophrenia is the genetic association for the human 
leukocyte antigen (HLA) region in the short arm of chro-
mosome 6.4
Microglia are the resident immune cells in the brain, 
compromising around 15% of total cells in the central 
nervous system (CNS).5 Microglia can be activated either 
in response to a systemic inflammatory challenge or 
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through the process of priming, whereby different stimuli 
sensitize the microglia so that a weak stimulus is able to 
produce an exaggerated immune response.6 Priming is 
key in triggering immune and inflammatory responses 
within the CNS; eg, stress-induced immune activation 
can lead to some psychotic symptoms.5 This compliments 
the theory that infection early in childhood, followed by 
either re-infection or exposure to new stimuli may induce 
a release of sensitized cytokines resulting in neurotrans-
mission disturbances.6
Microglial activation and subsequent cytokine produc-
tion have the ability to disrupt the blood–brain barrier, 
thus allowing movement of some inflammatory cytokines 
and other molecules into the brain.7 Altered cytokine lev-
els are found in both drug naïve, first-episode psychosis 
patients and chronically medicated patients, suggesting a 
problem independent of the effects of antipsychotic med-
ications.7 The concentrations of some inflammatory mol-
ecules may be clinically state-dependent. Inflammatory 
state-related markers include interleukin 1-beta (IL-1ß), 
IL-6, transforming growth factor beta (TGF-ß); the con-
centrations of these molecules are increased during acute 
psychotic episodes, returning to normal levels during 
the period of clinical stability.8 IL-12, interferon-gamma 
(IFN-γ), and tumor necrosis factor alpha (TNF-α) are 
inflammatory markers that are elevated in peripheral 
blood in both stable patients and first-episode psychoses.8 
Degraded products of inflammatory molecules have been 
identified in the cerebrospinal fluid (CSF) and brain tis-
sues in around 50% of patients with schizophrenia.9 These 
observations suggest that there are significant changes in 
the inflammatory signaling process at least in a subgroup 
of schizophrenia patients. Gross inflammatory changes 
have not been found in neuroimaging or neuropatho-
logical studies of schizophrenia, but a decrease in brain 
volume has been observed as early as the first episode of 
psychosis occurs, followed by progressive loss in brain 
volume during further development of the disease.9
Infection during a critical period of brain development 
may increase risk of developing schizophrenia later in 
life.10 Antibodies against different viruses were detected 
although these findings have been inconsistent across the 
studies.11 A  recent study reported that 20% of patients 
with first-episode psychosis carried serum antibodies 
against neuronal cell surface molecules.12 Schizophrenia-
associated changes in immunoglobulin levels in both 
plasma and CSF support an immunological role in the 
pathogenesis of the disease.11 Benros et al13 have recently 
reviewed evidence that pre-existing autoimmune disease 
might be a risk factor for schizophrenia, according to the 
link between schizophrenia and coeliac disease, rheuma-
toid arthritis, and other autoimmune conditions.
Goldsmith and Rogers14 investigated the role of auto-
immunity in schizophrenia and found contrasting reports 
of autoantibody levels, due to heterogeneity between 
studies and failure to account for the confounding effects 
of antipsychotic medication. The current study aimed to 
identify potential autoantigens encoded by selected genes 
present in schizophrenia-associated loci confirmed in the 
2014 GWA study and to explore the association of circu-
lating autoantibodies with schizophrenia.
Methods
Study Samples
A total of 356 archived plasma samples collected 
from patients with schizophrenia (n  =  169, 132 males 
and 37 females), aged 42.0  ±  13.3  years, and con-
trol subjects (n = 187, 125 males and 62 females), aged 
44.1 ± 12.8 years, were used to examine circulating anti-
bodies against the linear peptide antigens derived from 
the target proteins. These case–control samples were col-
lected through the University of Aberdeen in the period 
between 2003 and 2008, and stored long term at −80°C 
without thawing until they were aliquoted for antibody 
testing. Subjects were all classified as British Caucasian 
including English, Scottish, Welsh, and Irish individuals. 
All healthy controls had no previous history or current 
diagnosis of any mental health condition. All patients 
were diagnosed as having schizophrenia based on the 
DSM-IV criteria. Antipsychotic drugs prescribed to 
schizophrenia patients at the time of sampling are listed 
in supplementary table S1, with 128 patients taking a 
single antipsychotic drug, 14 taking more than one drug, 
and 27 without medication details. All control subjects 
were recruited during the same period from local commu-
nities and screened for psychiatric disorders as described 
previously.15 All subjects gave written informed consent 
to donate blood samples for the study of the pathogen-
esis of schizophrenia. This study was approved by a local 
ethics committee and conformed to the provisions of the 
Declaration of Helsinki.
Detection of Antibodies Against Linear Peptide 
Antigens
Target proteins encoded by the genes harboring or near 
to the index SNPs confirmed recently were identified 
from the NCBI protein database (http://www.ncbi.nlm.
nih.gov/protein).4 They were selected based on the fol-
lowing criteria: 1) the genes were highly expressed in both 
B-lymphocytes and brain tissues based on the BioGPS 
gene expression database (http://biogps.org), 2)  odds 
ratio (OR) from combined samples should be >1.08 or 
<0.93 based on the GWA study, and 3)  the number of 
genes present in a schizophrenia-associated locus of in-
terest should be less than 3.4 A total of 15 proteins were 
selected in this study, which are encoded by the follow-
ing genes: NRGN, TCF4, MMP16, ZNF804A, VRK2, 
CACNA1C, DPYD, SLC39A8, DRD2, TSNARE1, 
MAD1L1, TRANK1, FANCL, ERCC4, and IGSF9B. 
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Supplementary table S2 summarizes their location in the 
human genome, index SNPs, and physiological function.
Linear peptide antigens were designed based on the 
computational prediction of the HLA-II epitopes and 
on the epitope information for human disease in the 
Immune Epitope Database (http://www.iedb.org/). All 
peptide antigens were synthesized by solid-phase chem-
istry with a purity of >95% (Severn Biotech Ltd). An in-
house enzyme-linked immunosorbent assay (ELISA) was 
developed in-house with each antigen listed in table 1 to 
coat maleimide activated 96-well plates (ThermoFisher 
Scientific) according to the manufacturer’s guidelines. 
Each peptide antigen was dissolved in 67% acetic acid to a 
concentration of 5 mg/ml and stored at −20°C. The stock 
solution of each antigen was then diluted in coating buf-
fer (0.1 M phosphate buffer containing 0.15 M NaCl and 
10 mM EDTA, pH 7.2) to a concentration of 20 µg/ml as 
working solution. Each plate was coated with 100 µl of 
working solution and incubated overnight at 4°C. Plates 
were washed 3 times using 200 µl of  wash buffer 1 (0.1 
M phosphate buffer containing 0.15 M NaCl and 0.05% 
Tween-20, pH 7.2), and blocked using 10 µg/ml cysteine 
in coating buffer for 1 h at room temperature. Plates were 
washed twice with 200 µl of  wash buffer 1 and dried at 
40°C for 2 h. Plates, once dried, were sealed with sealing 
film and stored at 4°C until use. Sealing film was removed 
just before use and the plates were washed twice with 
200 µl of wash buffer 2 (phosphate-buffered saline (PBS) 
containing 0.1% Tween-20), in each well to rehydrate. 
The plasma sample (including positive control, PC) was 
diluted 1:150 in assay buffer (PBS containing 0.5% bovine 
serum albumin) and 50 µl of  the sample was loaded into 
each sample well; 50 µl of  assay buffer was added to each 
negative control (NC) well. Following incubation at room 
temperature for 90 minutes, the plate was washed 3 times 
with 200 µl of  wash buffer 2 and 50 µl of  peroxidase-
conjugated goat anti-human IgG Fc (ab98624, Abcam) 
diluted 1:50 000 in assay buffer was then added and incu-
bated for 60 min at room temperature. After incubation 
the plate was washed 3 times with 200 µl of wash buffer 2, 
50 µl of  3,3′,5,5′-tetramethylbenzidine (TMB, SB02, Life 
Technologies) was added and the plate was incubated 
in the dark for 20 min before 25 µl of  the stop solution 
was added (SS04, Life Technologies). The optical density 
(OD) of each well was then measured within 10 min with 
a plate reader at 450 nm with a reference wavelength of 
620 nm. All samples were tested in duplicate and the spe-
cific binding ratio (SBR) was calculated for each sample 
using the following formula:
SBR
OD OD
OD OD
sample NC
PC NC
=
–
–
Detection of Total IgG Levels and Double Stranded 
DNA Antibodies
To look at how specific each individual IgG test was in 
identification of schizophrenia subgroups, all plasma 
samples were tested for total IgG levels using the human 
IgG total Ready-SET-Go! ELISA kit (ThermoFisher 
Scientific) and also for IgG antibodies against double-
stranded DNA using the anti-dsDNA-NcX ELISA (IgG) 
kit (EUROIMMUN UK Ltd).
Data Analysis
Shapiro–Wilk statistic was used to test a normal distribu-
tion of the resulting data; 15 of the 18 tests showed sig-
nificantly skewed distributions in the patient group and 
14 in the control group (supplementary table S3). Mann–
Whitney U-test was thus used to examine the differences 
Table 1. Sequences of Peptide Antigens Derived From Target Proteins Tested
Antigen Name Protein Coding Gene Sequence
DPYD1 DPYD DIE SIL ALN PRT QTH ATL CST SAK KLD
CA1Ca CACNA1C CKLSWQAAIDAARQAKLMGSAGNATI
ARE1a TSNARE1 RCW LQE LFQ EMS ANV FRI NSS VTS LER
SLC39a SLC39A8 DFV ILL NAG MST RQA LLF NFL SAC SH
D1L1a MAD1L1 LIE VHL RRQ DSI PAF LSS ELF SRC
F804A-1 ZNF804A ECY YIV ISS THL SNG HFR NIK GVF RGP LID
NRGN-1 NRGN CDIPLDDPGANAAAAKIQASFRGHMARKKIK
TCF4a TCF4 CLK SDK PQT KLL ILH QAV AVI LSL EQQ VRE
SB2-1 TCF4 ILH QAV AVI LSL EQQ VRE RNL NPK AAC
VRK2a VRK2 CKT ISQ FTL SEE TNA DVY III PVL H
DRD2a DRD2 DLC AIS IDR YTA VAM PML YNT RYS SKR
MP16-1 MMP16 LLTFSTGRRLDFVHHSGVFFLQTLLWILC
MP16-2 MMP16 DVYTVFQFKRKGTPRHILYCKRSMQEWVD
SB2-2 TRANK1 CLQ WDP TYV KGV YRA GYS LLR LHQ RYE A
SB2-3 TRANK1 NIL ILS VRD ARD WLM KTE TRL KKE C
SB2-4 FANCL CKS LIS IYS QFL AAI ESL KAF WDV MDH
ERC4a ERCC4 CQE AFI LRL FRQ KNK RGF IKA FTD NAV D
F9B1 IGSF9B VYF QND LKL RVR ILI DGT LTI FRC
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in antibody levels between these 2 groups, and Spearman 
correlation analysis was applied to test the correlation in 
circulating levels between individual IgG antibodies tested 
and the correlation between total IgG levels and each 
individual IgG level; a P-value of <.003 was considered 
to be statistically significant as 18 antigens were tested 
in this study. Linear regression was applied to determine 
the effects, if  any, of the antipsychotic medication on the 
secretion of circulating antibodies with adjustment for 
age and sex. In such analysis, IgG levels were used as the 
dependent variable, and medication, age, and sex were 
used as the independent variables. Fisher’s combining 
probability test was applied to determine the combined 
P-value for each medication on overall antibody levels; a 
P-value of <.006 was considered to be statistically signifi-
cant, due to the number of groups tested.16 Receiver oper-
ating characteristic (ROC) curve analysis was carried out 
on each of the antigens to calculate the area under the 
ROC curve (AUC) with the in-house ELISA sensitivity 
against a specificity of ≥95% that was used to determine 
the cut-off  for calculation of the positive predictive value 
(PPV) and the negative predictive value (NPV). The coef-
ficient of variation (CV) was used to represent an inter-
assay deviation estimated using pooled plasma samples, 
called quality control (QC) sample, which were randomly 
collected from >20 healthy subjects and tested on every 
96-well plate.
Results
The reproducibility of the in-house ELISA test was 
excellent, with inter-assay deviation below 15% from 
every IgG assay (supplementary table S4). As shown in 
table 2, 9 of the 18 antigens tested in this study showed 
significant differences in plasma IgG levels between 
the patient group and the control group (P < .003), in 
which 6 showed an increase in plasma IgG levels includ-
ing DPYD1 (Z = −3.22, P = .001), D1L1a (Z = −4.05, 
P < .001), F804A-1 (Z  =  −3.41, P  =  .001), DRD2a 
(Z  =  −3.31, P  =  .001), SB2-3 (Z  =  −5.71, P < .001), 
and MP16-2 (Z = −3.99, P < .001), and 3 showed a de-
crease including ARE1a (Z = −6.47, P < .001), TCF4a 
(Z = −8.70, P < .001) and VRK2a (Z = −3.25, P = .001).
ROC curve analysis revealed that of 18 IgG tests, the 
anti-TRANK1 (SB2-3) IgG assay was the most sensi-
tive, with a sensitivity of 20.7% against the specificity of 
95.2% (AUC = 0.68, 95% CI = 0.62–0.73); anti-TCF4a 
IgG assay showed the largest AUC (AUC  =  0.78, 95% 
CI  =  0.73–0.83) but its sensitivity was just 10.7%. The 
remaining of IgG tests all had a sensitivity of less than 
15% (table 3).
Risperidone was the only antipsychotic drug that was 
likely to affect overall IgG levels (supplementary table 
S5) (combined P = .005) with individual effects on circu-
lating IgG against VRK2a (P = .018), F804A-1 (P = .01), 
ARE1a (P = .005), and SB2-4 (P = .007). All other anti-
psychotic drugs were not found to have significant effects 
on circulating IgG against these linear antigens tested. 
Kruskal–Wallis (supplementary table S6) analysis re-
vealed that risperidone could up-regulate the secretion of 
plasma IgG against VRK2a (H = 4.92, P = .027), ARE1a 
(H = 6.08, P = .014) and SB2-4 (H = 5.88, P = .015); how-
ever, all these tests failed to survive the Bonferroni cor-
rections. There was a significant correlation in circulating 
levels between all IgG antibodies tested (P < .003) in the 
patient group and between most IgG antibodies in the 
control group; their coefficients and P-values are given in 
tables 4 and 5.
Table 2. Analysis of Circulating IgG Against Each of 18 Antigens Tested
Antigens Patients, Mean ± SD (n) Controls, Mean ± SD (n) Z Pa
DPYD1 0.56 ± 0.24 (169) 0.48 ± 0.22 (187) −3.22 .001
CA1Ca 0.54 ± 0.34 (168) 0.51 ± 0.34 (187) −1.44 .150
ARE1a 0.36 ± 0.18 (169) 0.57 ± 0.37 (187) −6.47 <.001
SLC39a 0.46 ± 0.32 (169) 0.42 ± 0.28 (187) −1.40 .161
D1L1a 1.00 ± 0.25 (169) 0.90 ± 0.22 (187) −4.05 <.001
F804A-1 0.47 ± 0.17 (169) 0.42 ± 0.15 (187) −3.41 .001
NRGN-1 0.59 ± 0.29 (169) 0.56 ± 0.28 (187) −1.12 .240
TCF4a 0.21 ± 0.07 (169) 0.41 ± 0.21 (187) −8.70 <.001
SB2-1 0.72 ± 0.27 (169) 0.74 ± 0.24 (187) −1.18 .236
VRK2a 0.54 ± 0.18 (169) 0.61 ± 0.21 (187) −3.25 .001
DRD2a 0.82 ± 0.26 (169) 0.74 ± 0.25 (187) −3.31 .001
MP16-1 0.73 ± 0.28 (169) 0.69 ± 0.24 (187) −1.193 .233
MP16-2 0.42 ± 0.15 (169) 0.36 ± 0.13 (187) −3.99 <.001
SB2-2 0.84 ± 0.25 (169) 0.81 ± 0.21 (187) −1.30 .193
SB2-3 1.06 ± 0.63 (169) 0.75 ± 0.40 (187) −5.71 <.001
SB2-4 1.16 ± 0.39 (169) 1.14 ± 0.35 (187) −0.18 .856
ERC4a 1.01 ± 0.88 (169) 0.77 ± 0.59 (187) −2.90 .004
F9B1 0.85 ± 0.23 (169) 0.78 ± 0.21 (187) −2.67 .008
aP <.003 was considered to be statistically significant.
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Three individuals in the patient group and 3 in the 
control group were positive for double stranded DNA 
antibodies, and the chi-square test failed to show statis-
tically significant (χ2 = 0.02, P = .9). There was no sig-
nificant difference in total IgG levels (Z = 1.28, P = .221) 
between patients with schizophrenia (27.3 ± 10.8 mg/ml) 
and control subjects (26.7 ± 12.6 mg/ml); no significant 
correlation between total IgG levels and each individual 
IgG level was shown in either the patient group (supple-
mentary table S7) or the control group (supplementary 
table S8).
Discussion
The present study demonstrated that patients with 
schizophrenia had significant changes in circulating lev-
els of IgG antibodies against peptide antigens encoded 
by schizophrenia-associated genes.4 ROC curve analysis 
is a plot of the true positive against the false positive rate, 
the AUC provides a measure of how well each param-
eter is to distinguish between case and control groups. 
It is particularly important that the anti-TRANK1 IgG 
assay gave a sensitivity (true positive) of 20.7% against 
the specificity (true negative) of 95.2% (table 3) and failed 
to show a significant correlation with total IgG levels in 
plasma (supplementary tables S7 and S8), suggesting that 
anti-TRANK1 IgG test could serve as useful biomarker 
for a subgroup of schizophrenia. The TRANK1 gene is 
localized in the short arm of chromosome 3, 3p22.2, and 
encodes tetratricopeptide repeat and ankyrin repeat con-
taining 1. Although its function remains largely unclear, 
autoantibodies against TRANK1 protein (also called 
lupus brain antigen 1) have been reported to be associ-
ated with systemic lupus erythematosus (SLE).17 It is 
worth noting that the proportion of individuals positive 
for plasma IgG against double stranded DNA was less 
than 2% in our samples, with no difference between the 
case and control groups, suggesting that SLE is unlikely 
to be a cause of schizophrenia. A  recent study demon-
strated that IFN-α could up-regulate expression of the 
TRANK1 gene in differentiated hepatic cells by activa-
tion of the STAT-JAK pathway.18 The IFN pathway is 
involved in regulating the cellular innate immune sys-
tem to eliminate invading pathogens, so an increase in 
anti-TRANK1 IgG levels may disrupt IFN-mediated 
immune function in schizophrenia. Further investiga-
tion is required to explore the precise mechanism by 
which TRANK1 plays a central role in regulating IFN-
mediated immune response and protecting individuals 
from the development of schizophrenia.
All IgG antibodies tested in this study were significantly 
correlated to each other in the patients group (table 4) while 
most IgG antibodies (but not all tested) were significantly 
correlated to each other in the control group (table  5), 
suggesting that there may be something wrong with the 
humoral immunity in schizophrenia although there was no 
significant difference in total IgG levels between patients 
with schizophrenia and control subjects. Of 18 antigens 
studied, 6 showed an increase in circulating IgG levels in 
schizophrenia. The increased antibody levels may result 
from a breakdown of immune tolerance to the products 
of these schizophrenia-associated variants, causing an 
Table 3. ROC Curve Analysis of Plasma IgG Antibodies Against Each Antigen in Schizophrenia
Antigens Sensitivity (%)a AUC SE
Asymptotic 95% CI
PPV NPVLower Bound Upper Bound
DPYD1 12.5 0.60 0.030 0.54 0.66 0.72 0.52
CA1Ca 6.5 0.55 0.032 0.49 0.61 0.58 0.50
ARE1a 10.1 0.70 0.028 0.65 0.75 0.68 0.51
SLC39a 6.5 0.54 0.032 0.48 0.60 0.58 0.50
D1L1 11.2 0.62 0.030 0.57 0.68 0.70 0.52
F804A-1 11.8 0.61 0.030 0.55 0.67 0.71 0.52
NRGN-1 7.1 0.54 0.031 0.48 0.59 0.60 0.51
TCF4a 10.7 0.78 0.025 0.73 0.83 0.69 0.52
SB2-1 9.5 0.53 0.031 0.47 0.59 0.66 0.51
VRK2a 7.7 0.60 0.030 0.54 0.66 0.62 0.51
DRD2a 13.0 0.60 0.030 0.54 0.66 0.73 0.52
MP16-1 8.9 0.54 0.031 0.48 0.59 0.65 0.51
MP16-2 13.6 0.62 0.031 0.56 0.68 0.74 0.52
SB2-2 6.5 0.54 0.031 0.48 0.60 0.58 0.50
SB2-3 20.7 0.68 0.028 0.62 0.73 0.81 0.55
SB2-4 11.2 0.51 0.031 0.45 0.57 0.70 0.52
ERC4a 13.6 0.59 0.030 0.53 0.65 0.74 0.52
F9B1 5.9 0.58 0.030 0.52 0.64 0.55 0.50
Note: ROC, receiver operating characteristic; AUC, are under the ROC curve; PPV, positive predictive value; NPV, negative predictive 
value.
aAgainst a specificity of 95.2%.
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autoimmune response.14 Alternatively, this could result 
from a hyperactivity of the immune system as part of the 
etiology of schizophrenia, which would be concordant with 
current literature suggesting an increase in pro-inflamma-
tory molecules with an increased immune response in those 
undergoing both acute psychosis and chronic schizophre-
nia.11 Adjunctive trials of anti-inflammatory agents along-
side anti-psychotic medication have demonstrated only 
modest clinical gains, potentially targeting effect rather than 
cause.19 It could therefore be suggested that targeting of the 
immune system may gain more effective outcomes from 
clinical practices. Decreased antibody secretion was also 
observed in this study such as significant low levels of cir-
culating IgG against peptide antigens derived from TCF4, 
TSNARE1, and VRK2. Possibly, these IgG antibodies 
have a protective effect on schizophrenia. Several lines of 
research have suggested that natural antibodies play an 
important role not only in eliminating pathogens invaded 
but also in maintaining homeostasis of the immune system 
through suppression of inflammatory reactions.20,21 Since 
both autoantibodies and natural antibodies are produced 
by the B1 type of lymphocytes in the absence of external 
antigen stimulation or immunization, the balance between 
them may be very important for human health.22,23
Based on linear regression analysis (supplementary table 
S5), risperidone is the only antipsychotic drug affecting 
antibody levels in plasma, suggesting that its antipsychotic 
effect may partially depend on a regulatory process of the 
immune system. A systematic review demonstrated altered 
levels of some autoantibodies in drug-naïve patients with 
first-episode psychosis and also suggested a link between 
disease-associated SNPs identified and a number of autoan-
tibodies.24 Risperidone administration has previously been 
demonstrated to have an effect on inflammatory process 
and the immune system, consistent with our finding in this 
study.25,26 The relationship between anti-VRK2 IgG levels 
and risperidone treatment is particularly interesting. Those 
patients prescribed with the drug showed an increase in cir-
culating antibodies against VRK2 in comparison to con-
trols, whereas those who did not take risperidone appeared 
to have a significant decrease in this antibody level (supple-
mentary table S6). However, there is only a small number 
of the cases prescribed risperidone in comparison to the 
number of nonrisperidone prescriptions. This initial find-
ing needs replication in a large sample size.
There are several limitations in this study. First, it was 
impossible to fully control the confounding effects of life-
style factors such as alcohol consumption, diets, and use 
of any legal or illegal substances on the antibody levels 
measured, as samples were already collected and detailed 
information available was limited. Second, this study con-
tains no subjects who were either antipsychotic-free or drug-
naïve, so that the true effects of antipsychotic medication 
on the immune system may be masked or overestimated. 
Third, there was little clinical information of case–control 
subjects such as history of autoimmune disorders that may 
affect antibody analysis although the prevalence of severe 
autoimmune conditions is less than 4% in the European 
populations. It will also be useful to test these autoantibod-
ies in individuals with bipolar, major depressive disorders 
or other psychiatric diseases to determine if abnormali-
ties of the humoral immunity are limited to schizophrenia. 
Obviously, the addition of further control groups would 
demonstrate the possibility of using the findings of GWA 
study to identify autoantigen targets.
Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin online.
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